DR. GHASSAN JAMIL KOUSSA M.D.
Prescription History 1730341421
Internal Medicine - Pulmonary Disease in Oneida, NY


Quality Rating: 72.64 out of 100 score

NPI Status: Active since June 25, 2008

Contact Information

600 SENECA ST
ONEIDA, NY
ZIP 13421
Phone: (315) 361-7472
Fax: (315) 361-7473

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GHASSAN JAMIL KOUSSA M.D., an active Pulmonary Disease specialist practicing in Oneida, NY. Our medical registry currently tracks 19 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 542 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 81 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 81
30-Day Fills 103.0
Days Supply 2,248
NY State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills79.4
Peer Average Days Supply2,056
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,268.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.36

State Avg Cost Per Claim

$47.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 71
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.2
Peer Average Days Supply225
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $104.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.74

State Avg Cost Per Claim

$12.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 16.0
Days Supply 480
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills46.1
Peer Average Days Supply1,372
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,957.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$568.37

State Avg Cost Per Claim

$600.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills35.9
Peer Average Days Supply1,073
Conservative Utilization

This provider writes prescriptions for this formulation 37.0% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,736.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$219.81

State Avg Cost Per Claim

$300.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 30.3
Days Supply 620
NY State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.4
Peer Average Days Supply295
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $378.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.20

State Avg Cost Per Claim

$8.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 57.0
Days Supply 1,710
NY State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills50.0
Peer Average Days Supply1,491
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,267.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$664.79

State Avg Cost Per Claim

$531.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 67
30-Day Fills 87.0
Days Supply 2,587
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills52.7
Peer Average Days Supply1,578
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.4% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56,351.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$841.06

State Avg Cost Per Claim

$799.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 28.0
Days Supply 812
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills127.9
Peer Average Days Supply3,554
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,162.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$673.45

State Avg Cost Per Claim

$816.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Furosemide

Generic Formulation: FurosemideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 20.0
Days Supply 535
NY State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills131.7
Peer Average Days Supply3,744
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $55.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.11

State Avg Cost Per Claim

$6.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills39.9
Peer Average Days Supply1,175
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.5% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,115.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$374.16

State Avg Cost Per Claim

$468.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Levofloxacin

Generic Formulation: LevofloxacinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 103
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply229
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $76.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.81

State Avg Cost Per Claim

$8.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The L-isomer of Ofloxacin.

Therapeutic Applications

This medication is used to treat a variety of bacterial infections. Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 37.0
Days Supply 1,106
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills108.8
Peer Average Days Supply3,230
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $331.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.09

State Avg Cost Per Claim

$15.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply961
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $183,109.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,085.36

State Avg Cost Per Claim

$12,552.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 40.2
Days Supply 579
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,023
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $165.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.36

State Avg Cost Per Claim

$6.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 30.0
Days Supply 900
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,286
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,772.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$527.59

State Avg Cost Per Claim

$633.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 42
30-Day Fills 56.0
Days Supply 1,680
NY State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills49.7
Peer Average Days Supply1,490
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,579.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$537.60

State Avg Cost Per Claim

$516.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 66
30-Day Fills 82.0
Days Supply 2,460
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills73.7
Peer Average Days Supply2,206
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $54,787.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$830.11

State Avg Cost Per Claim

$849.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Varenicline Tartrate

Generic Formulation: Varenicline TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 350
NY State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply504
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,158.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$346.51

State Avg Cost Per Claim

$410.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Therapeutic Applications

Varenicline is used by adults to help stop smoking. To increase your chance of success, use this medication with a stop-smoking program that includes education, support, and counseling. Quitting smoking lowers your risk of heart and lung disease, as well as cancer. Varenicline works by blocking nicotine's effects in the brain that make you want to smoke. Discuss the risks and benefits of this medication, as well as other ways to quit smoking (such as nicotine replacement treatment), with your doctor.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 13.7
Days Supply 342
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply769
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,049.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$95.41

State Avg Cost Per Claim

$75.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GHASSAN JAMIL KOUSSA M.D. provides transparency into local medical care patterns within Oneida, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.